Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-controlled, 24-Week Study to Evaluate the Efficacy, Safety, and Tolerability of BBT-877, as Mono- or add-on Therapy, in Patients With Idiopathic Pulmonary Fibrosis (IPF)
NCT05483907 is registered in ClinicalTrials.gov with Bridge Biotherapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Double-blind, Placebo-controlled, 24-Week Study to Evaluate the Efficacy, Safety, and Tolerability of BBT-877, as Mono- or add-on Therapy, in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- Lead sponsor
- Bridge Biotherapeutics, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- April 12, 2023
- Completion date
- February 23, 2025
- Enrollment
- 129 (actual)
- Sites
- 44
Conditions
As the registry lists them; a condition with its own page is linked.